PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $21.00 target price on the stock.

Several other research analysts have also recently issued reports on the company. StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 9th. B. Riley cut their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a report on Monday, November 25th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

PDS Biotechnology Trading Down 6.0 %

Shares of NASDAQ PDSB traded down $0.08 during trading hours on Friday, reaching $1.26. The stock had a trading volume of 8,614,684 shares, compared to its average volume of 720,027. The business’s fifty day moving average price is $1.50 and its two-hundred day moving average price is $2.37. PDS Biotechnology has a 52-week low of $1.13 and a 52-week high of $6.00. The firm has a market cap of $48.12 million, a price-to-earnings ratio of -1.09 and a beta of 1.68. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55.

Institutional Trading of PDS Biotechnology

Several institutional investors have recently modified their holdings of PDSB. Geode Capital Management LLC lifted its position in shares of PDS Biotechnology by 9.8% in the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after purchasing an additional 37,142 shares in the last quarter. XTX Topco Ltd increased its position in shares of PDS Biotechnology by 241.8% during the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after purchasing an additional 47,528 shares during the period. Two Sigma Investments LP lifted its position in shares of PDS Biotechnology by 273.5% during the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after buying an additional 48,132 shares during the period. Jane Street Group LLC acquired a new stake in PDS Biotechnology in the 4th quarter valued at $58,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of PDS Biotechnology during the 4th quarter worth about $26,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.